Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “temozolomide” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 14
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 14 pipeline programs matching "temozolomide" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

14 results for “temozolomide” Back to intelligence hub

Search results

  1. Temozolomide

    Adaptive Biotechnologies Corp

    Glioblastoma

    phase 3 small molecule active

    1 trial
  2. Temozolomide

    GT Biopharma

    Glioblastoma

    phase 3 small molecule active

    1 trial
  3. Fibromun, Temozolomide SUN 100 mg hard capsules

    Philogen S.p.A.

    Glioblastoma

    phase 2 small molecule active

    1 trial
  4. Radiotherapy plus temozolomide

    The First People's Hospital of Lianyungang

    Glioma (Any Grade) in the Brain

    phase 2 small molecule active

    1 trial
  5. TEMOZOLOMIDE

    The George Institute

    Diffuse low-grade gliomas

    phase 2 small molecule active

    1 trial
  6. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial
  7. TEMOZOLOMIDE , IRINOTECAN

    Fondazione Telethon ETS

    Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy

    phase 2 small molecule active

    1 trial
  8. TEMOZOLOMIDE for locally advanced rectal cancer (LARC)

    Fondazione Telethon ETS

    locally advanced rectal cancer (LARC)

    phase 2 small molecule active

    1 trial
  9. Temozolomide

    PUMA BIOTECHNOLOGY, INC.

    Glioblastoma

    phase 2 small molecule active

    1 trial
  10. Temozolomide

    The First People's Hospital of Lianyungang

    Cytokine-Induced Killer Cells

    phase 2 small molecule active

    1 trial
  11. silevertinib in combination with temozolomide

    Blackmores Limited

    Glioblastoma (GBM)

    phase 2 small molecule active

    1 trial
  12. temozolomide

    Universal Integrated

    Cancer

    phase 2 small molecule completed

    1 trial
  13. temozolomide

    Children's Hospital of Fudan University

    Brain and Central Nervous System Tumors

    phase 2 small molecule completed

    1 trial
  14. Temozolomide

    Monte Rosa Therapeutics

    Brain Neoplasms, Malignant, Primary

    approved small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.